Multimodality Breast Imaging for Tumor Response in TNBC

Phase 1, open-label, single-arm trial of technetium-99m sestamibi in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Percent change in volume of index tumors and estimated area under receiver operating characteristic (ROC) curves assessed by digital mammogram, ultrasound, DCE-MRI and MBI up to 4 years, Percent change in tumor volume assessed by dynamic Tc99m-sestamibi MBI up to 6 months and 1 more. Started Nov 2016; status: active, not recruiting.